GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) » Definitions » Total Equity

GlaxoSmithKline Pharmaceuticals (BOM:500660) Total Equity : ₹0 Mil (As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals Total Equity?

GlaxoSmithKline Pharmaceuticals's total equity for the quarter that ended in Dec. 2024 was ₹0 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


GlaxoSmithKline Pharmaceuticals Total Equity Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals Total Equity Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18,206.05 14,782.60 26,629.56 17,412.73 17,776.40

GlaxoSmithKline Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 17,776.40 - 16,726.90 -

GlaxoSmithKline Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

GlaxoSmithKline Pharmaceuticals's Total Equity for the fiscal year that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=35566.175-17789.778
=17,776

GlaxoSmithKline Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives majority of its revenue from India.

GlaxoSmithKline Pharmaceuticals Headlines

No Headlines